Studies have reported a variable prevalence of brain metastasis at diagnosis of HER2-mutant NSCLC (from 9 to 30%), which seems to be less frequent in HER2-mutant compared to WT HER2 patients [43,57,63,64]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.